Ondansetron hydrochloride
Based on 11 publication(s) in Google Scholar
Ondansetron (GR 38032; SN 307) hydrochloride is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron hydrochloride exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron hydrochloride can inhibit nausea and vomiting induced by chemotherapy and radiotherapy.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 99614-01-4
- Formula: C18H20ClN3O
- Molecular Weight:329.82
-
Storage:
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ondansetron hydrochloride
More- Adv Sci (Weinh). 2025 Jul;12(26):e2503739. [Abstract]
- J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
- Int J Pharm. 2015 Dec 30;496(1):33-41. [Abstract]
- Front Pharmacol. 2024 Aug 21:15:1443169. [Abstract]
- Eur J Pharm Sci. 2023 Aug 1:187:106475. [Abstract]
- Biomedicines. 2026 May 3;14(5):1040. [Abstract]
- Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 2:122:110689. [Abstract]
- J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682.
- Biochem Biophys Res Commun. 2025 Oct 30:786:152756. [Abstract]
- SSRN. 2023 Srep 5.
- Patent. US20170319486A1.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IHC
All 5-HT Receptor Isoforms
More
Biological Activity
|
5-HT3 Receptor |
Ondansetron (2 mg/kg; i.p.; six consecutive days) hydrochloride exhibits anti-inflammatory effects in rats through the 5-HT3 receptor[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 99614-01-4
-
Appearance Solid
-
Molecular Weight 329.82
-
Formula C18H20ClN3O
-
Color White to off-white
-
SMILES
O=C1C(CN2C=CN=C2C)CCC(N3C)=C1C4=C3C=CC=C4.[H]Cl
-
Synonyms
GR 38032 hydrochloride; SN 307 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
The Locus Coeruleus-Periaqueductal Gray GABAergic Projection Regulates Comorbid Pain and Depression. [Abstract]2025 Jul;12(26):e2503739. PMID: 40192524 -
J Ethnopharmacol
Phytomedicine Fructus Aurantii-derived two absorbed compounds unlock antidepressant and prokinetic multi-functions via modulating 5-HT3/GHSR. [Abstract]2024 Apr 6:323:117703. PMID: 38185260
Ondansetron hydrochloride purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
Ondansetron (1 mg/kg; IP) had no impact on immobility time compared with the model group in rats.
Ondansetron hydrochloride purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
Ondansetron (1 mg/kg; IP) alone did not affect GE (gastric emptying) and IT (intestinal transit), overturning the gastrointestinal efficacy of hesperidin (MH).
Ondansetron hydrochloride purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
Ondansetron (1 mg/kg; IP) reversed the rise in 5-HT3 compared to the hesperidin (MH) group (68.42 ± 4.05 vs 78.85 ± 3.28 ng/mL).
-
Int J Pharm
Formulation and development of pH-independent/dependent sustained release matrix tablets of ondansetron HCl by a continuous twin-screw melt granulation process. [Abstract]2015 Dec 30;496(1):33-41. PMID: 25863118 -
Front Pharmacol
The therapeutic targets and signaling mechanisms of ondansetron in the treatment of critical illness in the ICU. [Abstract]2024 Aug 21:15:1443169. PMID: 39234104 -
Eur J Pharm Sci
Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes. [Abstract]2023 Aug 1:187:106475. PMID: 37225005 -
Biomedicines
Ferroptosis in Septic Cardiomyopathy Is Alleviated by Ondansetron: The Critical Role of the HTR3A-ATF3 Axis in Mitochondrial and Oxidative Homeostasis. [Abstract]2026 May 3;14(5):1040. PMID: 42193366 -
Prog Neuropsychopharmacol Biol Psychiatry
Baicalein exerts anxiolytic and antinociceptive effects in a mouse model of posttraumatic stress disorder: Involvement of the serotonergic system and spinal delta-opioid receptors. [Abstract]2023 Mar 2:122:110689. PMID: 36462602 -
Ondansetron hydrochloride purchased from MedChemExpress. Usage Cited in: J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682.
Ondansetron (ODN; 2 mg/kg; subcutaneously; 0-120 min) produced significant analgesia in both the Tail flick (TF) and hot plate (HP) tests compared with saline in rats.
Ondansetron hydrochloride purchased from MedChemExpress. Usage Cited in: J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682.
Ondansetron (ODN; 2 mg/kg; subcutaneously) decreased 5-HT3A immunoreactivity in rats dorsal root ganglia.
-
Biochem Biophys Res Commun
Dual-cardiotoxicity evaluation of torsadogenic risk drugs using human iPSC-derived cardiomyocytes. [Abstract]2025 Oct 30:786:152756. PMID: 41043280 -
-
Solvent & Solubility
DMSO : 50 mg/mL (151.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (15.16 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (15.16 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65. [Content Brief]
[2]. Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65. [Content Brief]
[3]. Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50. [Content Brief]
[4]. Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16. [Content Brief]
[5]. Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83. [Content Brief]
[6]. Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31. [Content Brief]
[7]. Xin Wang, et al. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys. 2015 Jun;72(2):471-3. [Content Brief]
[8]. Azadeh Motavallian-Naeini, et al. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. EXCLI J2012 Feb 22:11:30-44. eCollection 2012. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0320 mL | 15.1598 mL | 30.3196 mL | 75.7989 mL |
| 5 mM | 0.6064 mL | 3.0320 mL | 6.0639 mL | 15.1598 mL | |
| 10 mM | 0.3032 mL | 1.5160 mL | 3.0320 mL | 7.5799 mL | |
| 15 mM | 0.2021 mL | 1.0107 mL | 2.0213 mL | 5.0533 mL | |
| 20 mM | 0.1516 mL | 0.7580 mL | 1.5160 mL | 3.7899 mL | |
| 25 mM | 0.1213 mL | 0.6064 mL | 1.2128 mL | 3.0320 mL | |
| 30 mM | 0.1011 mL | 0.5053 mL | 1.0107 mL | 2.5266 mL | |
| 40 mM | 0.0758 mL | 0.3790 mL | 0.7580 mL | 1.8950 mL | |
| 50 mM | 0.0606 mL | 0.3032 mL | 0.6064 mL | 1.5160 mL | |
| 60 mM | 0.0505 mL | 0.2527 mL | 0.5053 mL | 1.2633 mL | |
| 80 mM | 0.0379 mL | 0.1895 mL | 0.3790 mL | 0.9475 mL | |
| 100 mM | 0.0303 mL | 0.1516 mL | 0.3032 mL | 0.7580 mL |
Ondansetron hydrochloride Related Classifications
HY-B0002 Related Classifications
Powered by Bioz